PT-141 (Bremelanotide)

Unverified protocol notes

Protocol logic check

Independent evidence

Regulatory status: approved drug label available for bremelanotide

Storage

Store at or below 25 C; do not freeze; protect from light.

Contraindications (limited evidence)

• Uncontrolled hypertension: PT-141 produces transient blood pressure increases (both systolic and diastolic) lasting 8-12 hours post-injection via MC4R-mediated sympathetic activation; in subjects with uncontrolled high blood pressure this cardiovascular effect represents meaningful added risk. Limited / unverified
• Severe or unstable cardiovascular disease (recent MI, unstable angina, significant arrhythmia): the transient BP elevation and sympathetic activation from MC4R agonism is contraindicated in subjects with marginal cardiovascular reserve. Limited / unverified
• History of significant orthostatic hypotension: PT-141 can produce transient hypotension in some subjects as the MC3R vasodilatory component briefly predominates; combined with orthostatic instability this creates fall and syncope risk. Limited / unverified
• Concurrent use with PDE5 inhibitors in subjects with cardiovascular disease: while the PT-141/PDE5 inhibitor combination is used in research, in subjects with significant cardiovascular disease the additive vasodilatory and hemodynamic effects require medical supervision. Limited / unverified
• Concurrent use with antihypertensive medications: MC4R-mediated sympathetic effects of PT-141 may transiently override antihypertensive therapy and produce unpredictable blood pressure excursions. Limited / unverified
• Known hypersensitivity to PT-141, bremelanotide, or melanocortin-derived peptides. Limited / unverified
• Pregnancy: MC4R agonism has effects on HPA axis and hypothalamic function not established as safe during pregnancy. Limited / unverified
• Breastfeeding: no safety data. Limited / unverified
• Active psychiatric conditions requiring mood stabilizers or antipsychotics: MC4R agonism affects dopaminergic tone in limbic circuits that overlap with the targets of these medications. Limited / unverified
• History of priapism or predisposition to prolonged erection (sickle cell trait, multiple myeloma, leukemia): PT-141's central arousal mechanism can trigger prolonged erections in predisposed subjects. Limited / unverified

Side effects (limited evidence)

• Nausea: the primary, most common, and most clinically impactful adverse effect; occurs in the majority of subjects at doses of 1.0mg and above; caused by MC4R activation in the area postrema (chemoreceptor trigger zone); onset within 30-60 minutes of injection; duration typically 1-4 hours; managed by microdosing (500mcg) or prophylactic antiemetics. Limited / unverified
• Flushing: facial and upper body flushing from MC3R/MC4R-mediated cutaneous vasodilation; immediate onset; typically lasts 1-2 hours; more pronounced at higher doses. Limited / unverified
• Transient blood pressure increase: systolic BP elevation of 6-8 mmHg and diastolic 4-6 mmHg documented in clinical trials; onset within 30 minutes; duration 8-12 hours; the primary cardiovascular safety concern. Limited / unverified
• Headache: common; related to the transient blood pressure changes and MC4R-mediated cerebrovascular effects; typically resolves within 1-2 hours. Limited / unverified
• Priapism (prolonged erection): rare but serious; unresolved erections lasting more than 4 hours require emergency medical intervention to prevent ischemic penile damage; more likely at higher doses or in predisposed subjects. Limited / unverified
• Spontaneous erections: MC4R activation in the hypothalamus produces erections independent of sexual stimulation; a desired effect in the ED indication but problematic in the wrong context. Limited / unverified
• Fatigue and lethargy: post-arousal effect as the acute MC4R activation wave resolves; typically 2-4 hours after peak effect. Limited / unverified
• Yawning: a distinctive and frequently reported MC4R activation marker; not pathological but a reliable signal of PT-141 activity onset. Limited / unverified
• MC4R desensitization with frequent use: the rationale for the 2-dose-per-week maximum; high-frequency MC4R agonism produces receptor downregulation and tachyphylaxis; the 16-week daily protocol's lower doses mitigate this but the 8-week washout is required. Limited / unverified
• Transient skin hyperpigmentation: MC1R is activated to a lesser degree than in Melanotan I/II but some subjects note mild transient darkening of moles or skin tone with repeated use. Limited / unverified
• Injection site reactions: mild bruising, erythema, and soreness at the subcutaneous site. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

None listed.

Reported contraindicated combinations:

None listed.

Sources

• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf